牛牛AI助理已提取核心訊息
On January 19, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that it had received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum closing bid price requirement. The company's stock had closed below the $1.00 minimum bid price for 30 consecutive business days. Despite the notice, Apollomics' shares continue to be listed and traded on the Nasdaq Capital Market under the ticker symbol 'APLM'. The company has been granted a 180-day period, until July 15, 2024, to regain compliance with the bid price requirement. If Apollomics fails to meet the requirement within this timeframe, it may be eligible for an additional 180 days to achieve compliance, potentially through a reverse stock split. The company is actively monitoring its stock price and considering options to address the deficiency, but there is no guarantee of regaining or maintaining compliance with Nasdaq's listing requirements.
On January 19, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that it had received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum closing bid price requirement. The company's stock had closed below the $1.00 minimum bid price for 30 consecutive business days. Despite the notice, Apollomics' shares continue to be listed and traded on the Nasdaq Capital Market under the ticker symbol 'APLM'. The company has been granted a 180-day period, until July 15, 2024, to regain compliance with the bid price requirement. If Apollomics fails to meet the requirement within this timeframe, it may be eligible for an additional 180 days to achieve compliance, potentially through a reverse stock split. The company is actively monitoring its stock price and considering options to address the deficiency, but there is no guarantee of regaining or maintaining compliance with Nasdaq's listing requirements.
2024年1月19日，臨床階段的生物製藥公司Apollomics Inc. 宣佈已收到納斯達克股票市場有限責任公司的通知，表示未遵守最低收盤價要求。該公司的股票連續30個工作日收於1.00美元的最低出價以下。儘管有通知，但Apollomics的股票繼續在納斯達克資本市場上市和交易，股票代碼爲 “APLM”。該公司已獲准在2024年7月15日之前的180天期限內恢復對投標價格要求的遵守。如果Apollomics未能在這段時間內滿足要求，則可能有資格再過180天來實現合規，可能是通過反向股票拆分。該公司正在積極監控其股價，並考慮採取期權來彌補缺口，但無法保證恢復或保持對納斯達克上市要求的遵守。
2024年1月19日，臨床階段的生物製藥公司Apollomics Inc. 宣佈已收到納斯達克股票市場有限責任公司的通知，表示未遵守最低收盤價要求。該公司的股票連續30個工作日收於1.00美元的最低出價以下。儘管有通知，但Apollomics的股票繼續在納斯達克資本市場上市和交易，股票代碼爲 “APLM”。該公司已獲准在2024年7月15日之前的180天期限內恢復對投標價格要求的遵守。如果Apollomics未能在這段時間內滿足要求，則可能有資格再過180天來實現合規，可能是通過反向股票拆分。該公司正在積極監控其股價，並考慮採取期權來彌補缺口，但無法保證恢復或保持對納斯達克上市要求的遵守。
有用
沒用